Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6 inhibitors
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced new preclinical data on narazaciclib in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.